In patients with cancer, iTreg able to produce ADO and PGE2 accumulate in tissues and blood and may be resistant to conventional oncological therapies (Schuler et al., in revision), so that silencing of these cells appears to be advisable. This evidence concerns the gene ADO and cancer.